Health
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children with insomnia disorder, with especially pronounced efficacy in those with co-morbid neurodevelopmental disordersExcellent safety and tolerability of daridorexant confirmed for the first time in a pediatric population – including at the highest dose testedIdorsia to engage with hea
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hFCnMmy9Ihh7UbzaqwJr7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children with insomnia disorder, with especially pronounced efficacy in those with co-morbid neurodevelopmental disorders","length":288,"tagName":"p"}]},{"val":[{"type":"text","content":"Excellent safety and tolerability of daridorexant confirmed for the first time in a pediatric population – including at the highest dose tested","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Idorsia to engage with health authorities to discuss next steps in pediatric insomnia and explore the potential of daridorexant for children with neurodevelopmental disorders","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"Idorsia to host an investor webcast to discuss the study tomorrow, March 31, at 15:00hrs CEST","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":698,"olType":false},{"type":"text","content":"Allschwil, Switzerland – March 30, 2026Idorsia Ltd (SIX: IDIA) announces positive top-line results from its Phase 2 dose-finding study evaluating 10, 25, and 50 mg doses of daridorexant – the company’s dual orexin receptor antagonist (DORA) – in pediatric patients aged 10 to < 18 years with insomnia disorder.","length":314,"tagName":"p"},{"type":"text","content":"Pediatric insomnia is characterized by difficulty initiating or maintaining sleep that is perceived as a problem by the child or caregiver due to its severity, chronicity, frequency, and the significant daytime impairment it causes for the child or the family.","length":260,"tagName":"p"},{"type":"text","content":"...